505496702 05/28/2019

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5543506

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
CHIRALVISION B.V.	09/01/2017

RECEIVING PARTY DATA

Name:	ALCRESTA THERAPEUTICS, INC.	
Street Address:	ONE NEWTON EXECUTIVE PARK	
Internal Address:	SUITE 100	
City:	NEWTON	
State/Country:	MASSACHUSETTS	
Postal Code:	02462	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16287543

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: JNGUYEN@BOMCIP.COM
Correspondent Name: JACQUELNE M. NGUYEN

Address Line 1: 2020 K STREET NW

Address Line 4: WASHINGTON, D.C. 20006

ATTORNEY DOCKET NUMBER:	11896-0001-02000	
NAME OF SUBMITTER:	JACQUELINE M. NGUYEN	
SIGNATURE:	/Jacqueline M. Nguyen, Reg. No. 75,321/	
DATE SIGNED:	05/28/2019	

Total Attachments: 2

source=2019-05-07 Assignment_CV to Alcresta 00389371#page1.tif source=2019-05-07 Assignment_CV to Alcresta 00389371#page2.tif

PATENT 505496702 REEL: 049297 FRAME: 0940

JOINT INVENTION (Worldwide Rights) Attorney Docket Nos. 11896-0001-01000 11896-0001-01000

ASSIGNMENT

WHEREAS, **ChiralVision B.V.**, a corporation of the Netherlands, whose post office address is J.H. Oortweg 21, NL-2333CH Leiden, the Netherlands (hereinafter referred to as Assignor), has made a new and useful invention described in patent applications entitled:

ENTERAL FEEDING DEVICES AND RELATED METHODS OF USE

for which Assignor owns right, title, and interest in and to applications for United States Letters Patent filed in the U.S. Patent and Trademark Office ("USPTO"), and identified in the USPTO by Application No. 62/241,608, filed on October 14, 2015, and a non-provisional application for United States Letters Patent filed in the USPTO, and identified in the USPTO by Application No. 15/291,530, filed October 12, 2016 (collectively, "Invention"); and

WHEREAS, **Alcresta Therapeutics, Inc.**, a corporation of Massachusetts whose post office address is One Newton Executive Park, Suite 100, Newton, MA 02462 (hereinafter referred to as Assignee), is desirous of securing and memorializing its entire right, title, and interest in and to this invention in all countries throughout the world, and in and to the applications for United States Letters Patent on this invention and any Letters Patent to be issued upon this application or any application claiming priority to this application;

NOW THEREFORE, be it known that, for good and valuable consideration, the receipt of which from Assignee is hereby acknowledged, Assignor has sold, assigned, transferred, and set over, and does hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, its entire right, title, and interest in and to this invention, Application No. 62/241,608, filed on October 14, 2015, Application No. 15/291,530, filed October 12, 2016, all nonprovisional applications, divisions, and continuations thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues thereof, and all rights to claim priority on the basis of the above applications and/or Letters Patent, and all applications for Letters Patent which may hereafter be filed for this invention in any foreign country and all Letters Patent which may be granted on this invention in any foreign country, and all extensions, renewals, and reissues thereof; and hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, Assignor HEREBY covenants that it has the full right to convey the interest assigned by this Assignment, and has not executed and will not execute any agreement in conflict with this Assignment;

AND, Assignor HEREBY further covenants and agrees that it will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to Assignor and its officers and employees respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all provisional, nonprovisional, divisional, continuation, and reissue applications, make all

9

SOLE/JOINT INVENTION (Worldwide Rights) Attorney Docket No. 11896-0001-01000

rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

Name/Title: <u>Dr. Rob Schoevaart, Managing Director</u>

ChiralVision B.V. J.H. Oortweg 21 NL-2333CH Leiden the Netherlands

Signed:

September 1st, 2017

Date:

Page 2 of 2

RECORDED: 05/28/2019

PATENT REEL: 049297 FRAME: 0942